No Data
No Data
Hong Kong stocks have experienced abnormal movement, with the concept of innovative drugs leading the way. The National Medical Products Administration has accelerated the approval of clinical pharmaceuticals, and many biotech companies have turned losses
Innovative drug concept has the highest increase. As of the time of writing, Akeso (01541) rose 60.42%, to HKD 6.16; Innocare (09926) rose 12.17%, to HKD 63.15; Innocare (09969) rose 6.19%, to HKD 5.83; Kanoa-B (02162) rose 5.56%, to HKD 39.85.
HK Stock Market News: Kangnova-B (02162) surged over 5% in the morning. CM310 adult AD indications approved. Two other indications have already submitted NDA.
Konoa-B (02162) rose more than 5% in the morning. As of the time of writing, it has risen 3.97% to HKD 39.25, with a turnover of HKD 81.3695 million.
gtja: Maintain a "shareholding" rating for Kangnaoya-B(02162). The first domestically produced IL-4R monoclonal antibody Kangyueda has been approved.
gtja maintains the revenue forecast for Kangnaoya-B (02162) from 2025 to 2026 at 0.526/1.441 billion yuan.
Express News | Stapokibart Was Granted Marketing Approval From National Medical Products Administration for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Kanoya-B (02162.HK): Sirupchiba received approval from the National Medical Products Administration for listing for the treatment of moderate to severe atopic dermatitis in adults.
Gelonghui, September 12th - Canoy-B (02162.HK) announced that the China National Medical Products Administration (NMPA) has recently approved the new drug application for Sipuche Baimonoclonal antibody (anti-IL-4Rα monoclonal antibody, trade name: Konyodar, research and development code: CM310) for adult moderate to severe atopic dermatitis. The approval for Sipuche Baimonoclonal antibody to go on the market is based on a multicenter, randomized, double-blind, placebo-controlled Phase III study, achieving at least 75% improvement in eczema area and severity index from baseline to week 16 (EASI-75) and overall assessment by researchers.
Express News | KeyMed Biosciences - Stapokibart Was Granted Marketing Approval From China's Nmpa
No Data
No Data